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Abstract
The human lectin-like oxidized low density lipoprotein receptor 1 LOX-1, encoded by the ORL1 gene, is the major scavenger
receptor for oxidized low density lipoprotein in endothelial cells. Here we report on the functional effects of a coding SNP,
c.501G.C, which produces a single amino acid change (K.N at codon 167). Our study was aimed at elucidating whether
the c.501G.C polymorphism changes the binding affinity of LOX-1 receptor altering its function. The presence of p.K167N
mutation reduces ox-LDL binding and uptake. Ox-LDL activated extracellular signal-regulated kinases 1 and 2 (ERK 1/2) is
inhibited. Furthermore, ox-LDL induced biosynthesis of LOX-1 receptors is dependent on the p.K167N variation. In human
macrophages, derived from c.501G.C heterozygous individuals, the ox-LDL induced LOX-1 46 kDa band is markedly lower
than in induced macrophages derived from c.501G.C controls. Investigation of p.K167N mutation through molecular
dynamics simulation and electrostatic analysis suggests that the ox-LDL binding may be attributed to the coupling between
the electrostatic potential distribution and the asymmetric flexibility of the basic spine residues. The N/N-LOX-1 mutant has
either interrupted electrostatic potential and asymmetric fluctuations of the basic spine arginines.
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Introduction
Many biochemical and functional studies have suggested a
fundamental role of oxidized low density lipoproteins (ox-LDL)
and of their main receptor LOX-1 (oxidized low density
lipoproteins receptor 1) in the pathogenesis of atherosclerosis [1,2].
LOX-1 is a disulfide-linked homodimeric type II transmem-
brane receptor belonging to the C-type lectin family of scavenger
receptors. Each subunit is composed by a short 34-residue
cytoplasmic region, a single transmembrane segment, and an
extracellular 80-residue ‘‘neck’’ domain, predicted to have a coiled
coil structure, followed by a 130-residue C-terminal C-type lectin-
like domain (CTLD) [3]. The two CTLD domains form a heart-
shaped homodimer, consisting of two antiparallel b-sheets flanked
by two a-helices with three large loops protruding into the solvent.
This fold is stabilized by three conserved intra-chain disulfide
bonds and an inter-chain disulfide bridge, located at the N-
terminus [4,5]. On the basis of this structure LOX-1 has been
hypothesized to interact with ox-LDL with a 3:1 stoichiometry [4].
It is expressed in endothelial cells, smooth muscular cells,
monocytes/macrophages, platelets, fibroblasts and cardiomyocites
[3,6–8]. LOX-1 activation elicits endothelial dysfunction, a key
step in the initiation of atherosclerosis, favouring generation of
reactive oxygen species, inhibition of nitric oxide synthesis, and
enhancement of monocyte adhesion to activated endothelial cells
[9]. In addition, LOX-1 is involved in foam cells formation and in
inducing smooth muscle cell migration, proliferation and trans-
formation [1].
In vascular endothelial cells, upon recognition of ox-LDL,
LOX-1 stimulates several intracellular signaling pathways, includ-
ing protein kinases such as p38 (MAPK), protein kinase C and
extracellular-signal-regulated kinase (ERK) 1/2 [10–13]. These
signaling pathways activate transcription factor NF-kB, which
elicits pro-inflammatory and pro-apoptotic gene expression [14]
contributing to the altered cellular function associated with
atherogenesis and plaque vulnerability. Recently, several associa-
tion studies have characterized various polymorphisms (SNPs,
single nucleotide polymorphisms) in OLR1 gene, that encodes for
LOX-1 receptor [15–17]. It was shown that a linkage disequilib-
rium block of SNPs located in the OLR1 gene introns 4, 5, and the
39 untranslated region are associated to an increased susceptibility
to acute myocardial infarction (AMI). These SNPs modulate the
expression of a splicing isoform of LOX-1 receptor, named
LOXIN, which protects macrophages against ox-LDL-mediated
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interacts with LOX-1 receptors inhibiting its function through the
formation of non-functional hetero-oligomers [18]. However,
conflicting results have been reported on the association between
some polymorphisms in OLR1 gene and coronary artery disease
(CAD)/AMI susceptibility on the basis of study design, statistical
analysis and interpretation of results [19]. In particular, a
predicted functional SNP, the G.C transition at position 501 in
the exon 4 has been studied, with different conclusions, as a
possible valid genomic biomarker for potential CAD/AMI risk
factor [15,20–23]. This SNP results in the Lys to Asn amino acid
residue replacement at position 167 of the C-type lectin-like
domain, in the extracellular portion of LOX-1 receptor. Since this
is the ligand binding domain, the p.K167N variation may affect
LOX-1 receptor response.
In order to test the effects of the p.K167N SNP, we investigated,
at a molecular level, whether the c.501G.C polymorphism could
affect LOX-1 receptor activity. Here we report the heterologous
expression and functional characterization of wild–type (K/K167)
and mutated (N/N167 and K/N167) LOX-1 in different cell lines,
including fibroblasts and human endothelial cells. K167N
mutation of LOX-1 receptor markedly alters ox-LDL binding,
uptake and its intracellular signalling. Investigation of p.K167N
mutation through molecular dynamics (MD) simulations, coupled
with a time evolution analysis of electrostatic potential, provides an
explanation for the drastic reduction of LOX-1 function.
Results
Expression of N167-V5 tagged variant
The native K/K167 (wt-LOX-1-V5) and mutated N/N167
(mut-LOX-1-V5) proteins have been ectopically expressed in
different cell lines, including fibroblasts (COS) and human
endothelial cells (HUVEC) and studied by Western blot. As
shown in Figure 1A, an intense band at 48 kDa is visualized with
anti-V5 antibodies in extracts derived from COS cells expressing
wt-LOX-1-V5 (lane 1) and mut-LOX-1-V5 (lane 3). In some gels
the 48 kDa protein is resolved as a doublet at 48 and 46 kDa and
an additive product is observed at 37 kDa (weak band in lanes 1
and 3). This is a degradation product immunoreactive with anti-
LOX-1 polyclonal antibodies. Removal of N-linked glycans by
PNGase treatment results in a band at 36 kDa and at 25 kDa,
representing the full length deglycosylated receptor and a smaller
degraded product of LOX-1 respectively (Figure 1A, lane 2). An
identical pattern is observed for mut-LOX-1-V5 (lane 4).
The two isoforms have been labelled for surface receptors in live
cells 24 hours after transfection (Figure 1B). A similar punctuate
plasma membrane-associated fluorescence is seen in cells express-
ing K/K LOX-1 (panel a) and N/N mut-LOX-1 (panel b). As
expected, when we compared the intracellular distribution of wt-
LOX-1 and mut-LOX-1 in fixed and permeabilized transfected
cells, we observed the same intracellular localization (not shown).
It is worth noting that similar patterns of expression were also
obtained in human endothelial cells HUVEC (data not shown).
Altogether these results indicate that the native and mutated
LOX-1 receptor undertake the same glycosylation/maturation
process and trafficking pathway.
Wt-LOX-1 and N167 variant interact and form hetero-
oligomers in vivo
The in vivo interaction between wt-LOX-1 and mut-LOX-1
isoforms in transfected cells has been studied by co-immunopre-
cipitation analysis. Constructs expressing myc-tagged wt LOX-1,
the non-relevant Sec-8H4-myc and the V5-tagged N/N167
proteins have been transiently co-transfected in COS cells, that
were processed for analysis 24 hours after transfection. Cellular
lysates were first immunoprecipitated with anti-V5 antibodies,
separated by SDS-PAGE and then immunoblotted with anti-Myc
Mab 9E10 to reveal wt-LOX-1-myc and Sec-8H4-myc. The
transfection efficiency and specificity of the experiment were
confirmed by analysing the input of LOX-1-myc and Sec8H4-myc
in extracts before immunoprecipitation. As it can be seen in
Figure 2A, a similar amount of myc-tagged proteins is present in
all samples (lanes 1–3). After immunoprecipitation with anti-V5
antibodies, the 48 and 46 kDa bands, corresponding to LOX-1-
myc, are observed either in extracts derived from cells expressing
LOX-1-V5 and in cells expressing mut-LOX-1-V5 (Figure 2B,
lanes 4 and 5). On the contrary, the non-relevant Sec8H4-myc
protein, used as a control, does not co-immunoprecipitate with
LOX-1-V5 (lane 6).
To detect and separate high molecular weight forms of LOX-1,
3–8% acrylamide gels have been used in non reducing conditions.
As it can be seen in Figure 2B (lane 1), in COS cells co-expressing
Figure 1. Ectopic expression of K/K167 and N/N167 LOX-1 variants. (A) Western blot analysis of lysates from COS cells transiently transfected
with wt-LOX-1-V5 (lanes 1–2) and N/N167 LOX-1-V5 (lanes 3–4) incubated with PNGase as indicated and immunoblotted with Mab anti-V5. Molecular
weight markers are given in kilodaltons (kDa) and are indicated on the left. (B) Surface localization of wt-LOX-1-V5 (panel a) and N/N167 LOX-1-V5
(panel b) expressed in COS cells was analyzed by indirect immunofluorescence with Mab anti-V5. Scale bar 10 mm.
doi:10.1371/journal.pone.0004648.g001
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expressed as a major 90 kDa band corresponding to the homo-
dimer and a minor band at 180 kDa corresponding to the homo-
tetramer. The expression of N/N167-LOX-1-V5 in the presence
of K/K-LOX-1-myc at a ratio 1:1 (lane 2) or expression of N/
N167 mutated LOX-1 alone (not shown) results in a similar
pattern, indicating the formation of higher molecular weight (MW)
oligomers.
In order to assess whether the two receptor isoforms form stable
hetero-oligomers, lysates derived from COS cells co-expressing
myc- and V5-tagged wt-LOX-1 and mut-LOX-1 were first co-
immunoprecipitated with anti-myc antibodies and then analysed
by Western blot with anti-V5 antibodies. As shown in Figure 2B,
one major band at 90 kDa corresponding to LOX-1 homo-dimers
and a 180 kDa band corresponding to the homo-tetramers are
present when wt-LOX-1-myc and wt-LOX-1-V5 were co-
transfected (lane 3), as also previously reported [18]. Immunopre-
cipitation of lysates derived from COS cells co-expressing wt-
LOX-1-myc and N/N167-LOX-1-V5 at a ratio 1:1 results in the
co-immunoprocipitation of the 90 kDa and 180 kDa bands,
corresponding to the wt-LOX-1/mut-LOX-1 hetero-dimers and
hetero-tetramers (lane 4).
Ox-LDL binding and uptake in wt-LOX-1 and mut-LOX-1
expressing cells
COS cells transfected with wt-LOX-1, mut-LOX-1 or LOXIN
have been incubated with DiI-ox-LDL at 4uC for 1 hour or at
37uC for 4 hours, to investigate the ox-LDL binding and uptake
respectively. DiI-ox-LDL efficiently binds to wild type LOX-1
receptors (Figure 3A, panel c). Incubation of these cells for 4 hours
at 37uC with DiI-ox-LDL leads to its uptake and accumulation
inside cells (panel b). Interestingly, a lower efficiency of DiI-ox-
LDL binding and uptake is observed in cells expressing the mut-
LOX-1 variant (panels e and f). No fluorescence can be visualized
in panels h and i, confirming that LOXIN expressing cells do not
bind DiI-ox-LDL [18].
Quantification of bound DiI-ox-LDL has been obtained by its
extraction with isopropanol and spectrofluorometric analysis. As
shown in Figure 3B, the decrease of ox-LDL binding and uptake is
15–20% in cells transfected with K/K167 and N/N 167-LOX-1
isoforms at a ratio 1:1 and 30–35% in cells expressing the N/N167
variant alone, when compared to the native protein. As previously
reported [18], the inhibition of ligand binding and its uptake is
almost complete in LOXIN expressing cells (Figure 3B). Notably,
as it occurs in cells that were simultaneously transfected with
LOX-1 and LOXIN, the co-transfection of K167N and LOXIN
at a ratio 1:1 leads to a marked inhibition of the receptor binding
activity (18 and data not shown).
We have also quantified the surface appearance of wt-LOX-1,
the two mut-LOX-1 variants and LOXIN by a cytoELISA assay.
The missense K167N mutation does not give any effect on LOX-1
receptors trafficking to the plasma membrane and a similar signal
is observed in cells transfected with wt-LOX-1 and mut-LOX-1
(Figure 3C). It is worth noting that, although the K167N variant
has a lower ox-LDL receptor activity, the amount of exposed
receptors is identical to the wild type LOX-1 receptor. On the
contrary, only 25% LOXIN molecules are exposed, confirming
that the LOXIN splice variant localizes mostly intracellularly [18].
ERK 1/2 activity is impaired by single K167N mutation
To evaluate whether single K167N mutation on LOX-1
receptor impairs ERK 1/2 kinase activity, we analyzed ERK 1/
Figure 2. In vivo interaction between wt-LOX-1 and mutated LOX-1 receptors. (A) COS cells were co-transfected with wt-LOX-1-myc and
wt-LOX-1-V5 (lanes 1 and 4), N/N167 LOX-1-V5 and wt-LOX-1-myc (lanes 2 and 5) and Sec-8H4-myc and wt-LOX-1-V5 (lanes 3 and 6) at a DNA ratio
1:1. Half lysates were immunoblotted with anti-myc antibodies (lanes 1–3) and the remaining extracted proteins were first immunopurified with anti-
V5 antibodies and then probed with anti-myc 9E10 (lanes 4–6). The migration of molecular weight markers (kDa) is indicated on the left and the
heavy (c) and the light (k) chains are indicated on the right. (B) Lysates of COS cells co-expressing wt-LOX-1-myc and wt-LOX-1-V5 (lane 1 and 3) and
wt-LOX-1-myc and N/N167 LOX-1-V5 (lanes 2 and 4) were separated by a NuPAGE 3–8% polyacrylamide gradient gel in non reducing conditions.
Lanes 1 and 2 represent the extracts immunoblotted with Mab anti-V5, while lanes 3 and 4 are the extracted proteins first immunopurified with
Rabbit anti-myc and then probed with Mab anti-V5. The dimers and tetramers are indicated, respectively, with D and T and the migration of
molecular weight markers (kDa) is indicated on the left. All experiments were repeated three times with similar results.
doi:10.1371/journal.pone.0004648.g002
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directed against the phosphorylated ERK 1/2 [12,13]. Wild-type
K/K-LOX-1, mutated N/N-LOX-1 and K/N-LOX-1 or
LOXIN have been transiently transfected in COS cells, incubated
with or without LDL or ox-LDL at different concentrations (from
10 to 100 mg/ml) and the phosphorylated-ERK 1/2 bands
compared. Incubation with 100 mg/ml of ox-LDL for 10 min
gives the optimal conditions for maximal LOX-1 dependent ERK
1/2 activation without cytotoxicity (not shown). Figure 4A shows
the result of one typical experiment. The fold increase in ERK
phosphorylation was evaluated by densitometric analysis of the
42 kDa phospho-ERK band (Figure 4B). As it can be seen, ox-
Figure 3. Effect of K167N mutation on LOX-1 ox-LDL binding and uptake. (A) Cells were incubated with 10 mg/ml of DiI-ox-LDL for 4 h at
37uC (uptake) or 1 h on ice (binding). Surface expressed K/K167-V5, N/N167-V5 or LOXIN-V5 proteins were visualized with Mab anti-V5 (panels a, d
and g respectively). Fluorescence of DiI-ox-LDL is shown in panels b, e and h in the uptake assay and in panels c, f and i in the binding assay. A strong
and specific fluorescence of DiI-ox-LDL was detected in cells transfected with K/K167 LOX-1 (panels b and c), while a lower signal was detected in cells
expressing N/N167 (panels e and f). No fluorescence was detected in cells expressing LOXIN (panels h and i). Scale bar 10 mm. (B) Binding and uptake
of DiI-ox-LDL in cells expressing K/K167, N/N167, K/N167 or LOXIN were measured by extraction of DiI fluorescence with isopropanol as described in
Materials and methods. (C) Surface receptors were measured by cytoELISA assay by using anti-V5 antibodies, as described in the text. The data
represent the average6standard deviation (SD) of four separate experiments. A p value (** p,0.01; * p,0.05) was considered to be statistically
significant; the ns label indicates no significant difference.
doi:10.1371/journal.pone.0004648.g003
Figure 4. Ox-LDL stimulated ERK 1/2 phosphorylation in COS cells. (A) COS cells were transiently transfected with pEF/V5-His empty vector
(Mock) or K/K167, N/N167, K/N167 or LOXIN variants. 48-h after transfection, cells were incubated with 100 mg/ml of LDL or ox-LDL, as indicated, for
10 minutes at 37uC. Cell extracts were immunoblotted with mouse anti-phospho-ERK 1/2 and rabbit anti ERK1/2.(B) Densitometric measurements
were performed to evaluate the fold increase in phospho-ERK 1/2 activation in the presence of ox-LDL. The data represent the average6standard
deviation (SD). A p value (** p,0.01) was considered to be statistically significant.
doi:10.1371/journal.pone.0004648.g004
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tors and the fold increase of activation is 8–10, when compared to
the intensity of the band observed in lysates derived from non
treated cells or cells treated with 100 mg/ml of LDL for 10 min.
This value is 1,2–2 in N/N-LOX-1 and 2–3 in K/N-LOX-1
expressing cells, indicating a marked decrease in the activation of
ERK pathway. Incubation with LDL did not induce phosphor-
ylation of ERK 1/2 kinases in cells transfected with K/N167 and
LOXIN (not shown). It is worth noting that, as expected, mock
transfected cells and cells expressing LOXIN variant do not show
any induction of phosphorylation of ERK 1/2 kinases.
Ox-LDL dependent LOX-1 induction is altered in
macrophages derived by c.501G.C heterozygous
individuals
Human monocytes have been isolated from peripheral blood
mononuclear cells(PBMCs) frombuffy coatsofvolunteers, genotyped
for the presence of K167N SNP and cultured in vitro for 11 days in
o r d e rt op r o m o t et h e i rt r a n s i t i o nt om a c r o p h a g e s ,b e f o r eo x - L D L
induction. Ox-LDL-dependent induction of endogenous LOX-1
receptors was studied by Western blot with anti-LOX-1 polyclonal
antiserum (Figure 5B). The intensity of the 46 kDa LOX-1 band in
lysates derived from ox-LDL-treated cells has been measured by
densitometric analysis and compared to the band present in lysates
derived from non treated cells. As it can be seen, LOX-1 band is
inducedinhuman differentiated macrophagesderivedfromwild type
volunteers (c.501G) in an ox-LDL dose-dependent manner. Incuba-
tion with 10 mg/ml of ox-LDL results in 3–4,5 fold increase in band
intensity, 50 mg/ml in 6,8–9,4 and 75 mg/ml in 15–18 fold increase
(Figure5A). Interestingly, inductionofLOX-1 receptor bandwasalso
dependent on the p.K167N SNP genotype. When differentiated
macrophages derived from c.501G.C (KN) patients have been
cultured in the absence or in the presence of 50 mg/ml ox-LDL and
analyzed for LOX-1 induction, the 46 kDa LOX-1 band increases of
2,8–3,6 fold (Figure 5A). This value is much lower than that obtained
in wild type c.501G (KK) derived macrophages and is similar to the
intensity obtained from these macrophages induced with 10 mg/mlof
ox-LDL (Figure 5B, compare lanes 5 and 7).
Positive electrostatic potential and asymmetric
fluctuations of basic spine arginines are altered in the
K167N mutants
In order to identify the structural-dynamical properties that are
responsible for altered receptor activity, comparative MD
simulations of the K/K, N/N and K/N-LOX-1 CTLD domain
have been carried out.
Figure 5. Ox-LDL-dependent LOX-1 induction in human macrophages derived by G501G and G501C individuals. (A) Densitometric
measurements (mean6SD) were performed to evaluate the fold increase in LOX-1 46 kDa band intensity. The endogenous expression of LOX-1 was
analysed by Western blotting with rat anti-human LOX-1 antiserum in human macrophages derived from 10 K/K and 3 K/N individuals incubated in
the absence or in the presence of 10, 50 or 75 mg/ml ox-LDL, as indicated. (B) Western blot of macrophages derived from K/K control and K/N
heterozygous individuals. Protein level was monitored by probing the same blot with anti-b-actin IgG. In lane 3 b-actin may resemble a doublet for a
small rupture of the gel.
doi:10.1371/journal.pone.0004648.g005
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trajectory (i.e. from 5 ns to 15 ns), where the three systems reach a
conformational stability, as monitored by time evolution of the
global Root Mean Square Deviation (RMSD), i.e. the displace-
ment from the starting structure (see Figure S1 of Supplementary
Data).
Mutation of K167 to N leaves the charged residue E170
uncoupled. In fact the salt bridge between K167 and E170,
present in the X-ray structure and stable in the wild type
simulation, is removed in the N/N-LOX-1 simulation and is
present only in the wild type monomer of the K/N-LOX-1
simulation. The residue E170, once lost its partner K167, is
unable to form a new stable salt bridge with any other positively
charged residue. E170, as a consequence of mutation, remains as
a free negative charge fluctuating on the LOX-1 surface,
influencing the electrostatic potential generated by the arginines
of the basic spine.
The electrostatic potential contour diagram of the CTLD
domains has been calculated at 2.0 kT/e for 20 representative
configurations each extracted every 500 ps from the trajectories.
Figure 6 shows the potentials for 4 representative configurations
(i.e. snapshots at 1.5, 4.0, 6.5 and 9.0 ns). The potential surface
for the wt-LOX-1 protein is wide and characterized by positive
values above the basic spine region (red isopotential surface in
Figure 6A and blue arginine residues in panel D), in line with the
proposed electrostatic recognition with the negatively charged
surface of ox-LDL [4,5]. On the contrary, K167 mutants show
alteration on the potential surface over the ox-LDL recognition
site, i.e. over the basic spine arginines that are distant from 23 to
51 A ˚ from the mutation site (Figure 6D). In the N/N and K/N-
LOX-1 variants (Figure 6B and 6C, respectively) the potential is
less regular when compared to the wild type. It has a reduced
positive lobes volume and a larger variability when observed as a
function of time. This result well correlates with the lower ox-
LDL recognition displayed by the N/N and the K/N mutants
described in Figure 3.
The fluctuations of the residues (i.e. the standard deviation of
residue position during the simulation) have been also monitored
from the MD simulations focusing the attention on the basic spine
residues. The main chain root mean square fluctuations (RMSFs),
calculated over the trajectories and averaged over each residue, for
the wt-LOX-1 and the two N/N and K/N-LOX-1 mutants,
indicate that most residues have fluctuations not higher than
0.2 nm, apart the C-terminal tails which reach values around
0.35 nm (Figure 7 A,B,C). The N-terminal tails are less flexible
due to the presence of the disulfide bridge between Cys140 of the
subunits A and B and reach values lower than 0.2 nm. In the three
proteins a relatively highly fluctuating region (values between 0.14
and 0.25 nm) is localized between Arg209 and Gly241, including
the loops L1, L2 and L3 and the two small b-strands: b2a and b2b
[4,5]. Although the three proteins display a similar pattern of
mobility, differences in fluctuations between the wt-LOX-1 and
the mutants are observed for the residues belonging to the basic
spine (i.e. arginines 208, 229, 231, 248). In the two subunits of the
wild type (Figure 7, panels A and D) the average fluctuation of the
arginines pairs is almost identical (the absolute value of their
difference ranging from 0.0 to 0.01 nm). On the contrary, in the
two monomers of the N/N-LOX-1 mutant (Figure 7, panels B and
D) the arginines pairs fluctuate differently. In detail, Arg229, 231
and 248 show an absolute value of their difference ranging from
0.04 to 0.08 nm. An intermediate fluctuation difference is
observed for the basic spine arginines of the K/N-LOX-1
monomers (the absolute value of their difference ranging from
0.02 to 0.04 nm) (Figure 7, panels C and D).
Discussion
Discordant results have been reported on the association of the
single nucleotide polymorphism c.501G.C of the OLR1 gene to
CAD/AMI. In one study, a higher frequency of LOX-1 gene
variants in Japanese patients with MI than in controls was found
[21]. While two different, but comparable studies reported a lower
frequency of 501 SNP in patients with acute myocardial infarction
than in controls, indicative of a positive association to MI [15,20].
More recently, however, two studies failed to replicate an
association of the coding c.501G.C SNP with CAD [19,23]. In
order to elucidate the mechanism by which the c.501G.C
polymorphism may influence the risk of atherosclerosis and MI,
we have performed a detailed biochemical and functional analysis
of the p.K167N mutation of LOX-1 receptor.
We have analysed the effects of heterologous expression of
p.K167N variant in mammalian fibroblasts and human endothe-
lial cells. We show that both wt-LOX-1 and mut-LOX-1 variant
display a stable dimeric structure and tend to form higher MW
oligomers in vivo. When the two proteins are co-transfected, they
form hetero-oligomers, in particular hetero-dimers and hetero-
tetramers. Moreover, they have the same glycosylation/matura-
tion process and the missense p.K167N mutation does not affect
LOX-1 receptor trafficking to the plasma membrane. Importantly,
when ectopically expressed, the amount of exposed receptors, at
the steady state, is identical. However, at a functional level, the
presence of p.K167N mutation in LOX-1 receptors reduces ox-
LDL binding and uptake. In particular, the binding activity is 30–
35% lower in case of homozygosity for N/N-LOX-1 expression
and 20% reduced in case of heterozygosity, obtained by co-
transfection of K/K167 and N/N167 DNA plasmids at a ratio
1:1. It is worth noting that the presence of the C-terminal tags
(myc- and V5-tags) in LOX-1 receptors and its variants does not
have any influence on the reported effects, as demonstrated by
transfection and functional analysis with the non-tagged proteins
(18 and unpublished results).
ERK 1/2 phosphorylation is specifically stimulated by ox-LDL
in LOX-1 expressing cells (12, 13 and Figure 4). Since p.K167N
mutation affects ox-LDL binding activity, we next examined the
activation of the extracellular signalling-regulated kinases ERK 1/
2 in K/K167, K/N and N/N167 transfected cells. Expression of
K/N and N/N167 LOX-1 receptors in fibroblasts resulted in a
marked inhibition of ERK activation (85% reduction in case of
homozigosis and 70% in case of heterozygosis) with respect to
ERK activation in wt LOX-1 expressing cells, indicating the
impairment of the ox-LDL-dependent intracellular response.
ERKs belong to a family of mitogen-activated protein kinases
associated to a variety of biological responses, depending upon the
cell type, the stimulus and the duration of activation. These
include also injury-induced tissue damage and apoptosis in some
cell types and organs [24]. Although we do not have evidences on
the downstream effects of the observed impairment of ox-LDL-
dependent ERK phosphorylation, further studies are likely to
clarify this important issue. It is worth noting that also expression
of the mutant form of LOX-1 protein K267A LOX-1 blocks
ERK1/2 activation [13]. Hetero-dimerization between mutated
and wild-type LOX-1 receptors attenuate the expression of
functional receptors and, therefore, the intake of ox-LDL inside
the cells.
The G-to-C transition of LOX-1 gene results in the K-to-N
change at 167, far from the basic spine arginines of the CTLD
domain that represents the ligand binding domain (Figure 6D).
From modeling studies, the first important effect of the single
p.K167N mutation is an altered balance of charges in the network
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PLoS ONE | www.plosone.org 7 February 2009 | Volume 4 | Issue 2 | e4648Figure 6. GRASP representations of the isopotential electrostatic distribution observed along the trajectory around (A) K/K167, (B)
N/N167 and (C) K/N167 LOX-1 mutants. Red surfaces represent the positive isopotential surface at 2.0 kT/e (where k is the Boltzmann constant,
T=298 K and 1kT/e=0.0257 V), blue surface the corresponding negative values. The protein boundaries are represented by a rendered molecular
surface. Isopotential surfaces in the protein interior are not drawn for clarity. Panel D shows the molecular surface of the CTLD domain representing
the location of the arginines composing the basic spine (blue) and the mutation site (green).
doi:10.1371/journal.pone.0004648.g006
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the mutation site and alterations, i.e. the uncoupled negative
charge of E170, are observed either in the homozygous N/N-
LOX-1 and in the heterozygous K/N-LOX-1 mutant. Secondly,
it was observed an asymmetric flexibility of the basic spine
residues, in particular in the N/N-LOX-1 mutant. We hypothesize
that the variation of potential distribution, observed in N/N-LOX-
1, is due both to an unbalanced network of charges and to an
altered flexibility of the basic spine residues that, together, induce a
marked inhibition of ox-LDL recognition. In the heterozygous K/
N-LOX-1 mutant the unbalanced network of charges alters the
potential distribution but is not supported by the basic spine
arginines large asymmetric fluctuation, explaining the lower level
of impairment.
Ox-LDL is considered to play a fundamental role in the entire
process of atherogenesis. LOX-1 activation by ox-LDL binding
rapidly induces a cascade of intracellular signalling leading to
endothelial activation, cell proliferation, apoptosis and atheroscle-
rosis [2]. Although LOX-1 is expressed at low level in normal
conditions, its expression is highly activated by ox-LDL binding
via intracellular signalling, indicating that pro-inflammatory
conditions create a positive feedback that enhance endothelial
dysfunction [9]. Interestingly, when in vitro differentiated human
macrophages, derived from K/N167 heterozygous individuals
were incubated with ox-LDL to study LOX-1 receptor synthesis
and induction, we found a marked decrease in ox-LDL-dependent
LOX-1 induction compared to the induction seen in differentiated
human macrophages derived from K/K167 control individuals.
The single aminoacid p.K167N mutation of LOX-1 receptor
induces decreased efficiency in ox-LDL binding and uptake,
affects its signal transduction activity and, in vivo, results in a
marked decrease in the induction of LOX-1 receptors upon stress
stimuli in human macrophages. All these effects may have a
marked influence on ox-LDL toxicity in vivo, and may affect the
severity of CAD and atherosclerosis. Interestingly, the frequency of
the heterozygous p.K167N LOX-1 is about 10% in Caucasian
population, while homozygous for the N allele are very rare [15].
Unfortunately, whether the LOX-1 induction in human macro-
phages derived from the homozygous N/N167 individuals is even
lower than in the heterozygosis could not be verified.
In conclusion, the lower LOX-1 activity in individuals carrying
the p.K167N mutation reported in this paper suggests that the
lysine residue at 167 is crucial for ligand binding activity of LOX-1
protein and for its function. This finding strengthens the idea that
specific inhibition of LOX-1 receptor may be a valuable
therapeutic strategy for combating atherosclerosis.
Figure 7. Average main chain residue RMSF of the two subunits of the CTLD domain of (A) K/K167, (B) N/N167 and (C) K/N167 LOX-
1. The A subunit is shown by a black line with black filled circles, while the B subunit is indicated by a grey line with gray filled circles. In panel C the
black and the grey lines represent the mutated and the wild type subunit, respectively. The arginines belonging to the basic spine are indicated by
large filled circles. The residues that in the X-ray starting structure are in a-helix and b-strand are indicated by the grey and black squares close to the
X-axis, respectively. (D) Differences between the average RMSF values of the basic spine arginine residues belonging to the two subunits of the CTLD
domain: wt (black), N/N (red) and K/N LOX-1 (green). The first subunit value is subtracted to the second subunit value.
doi:10.1371/journal.pone.0004648.g007
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DNA constructs and mutagenesis
For the expression in mammalian cells, human LOX-1 was
subcloned into pEF/myc-His and pEF/V5-His vectors (Invitro-
gen), LOXIN and R4 were subcloned into pEF/V5-His vector
(Invitrogen) as previously described [18].
Generation of pscFvexpress-Sec-8H4 has been previously
described [25]. Mutagenesis of Lys167 to Asn residue of Lox-1
was performed using QuikChangeH Multi Site-Directed Mutagen-
esis kit purchased from Stratagene following the manufacture’s
protocol. Mutagenesis of pEF/V5-LOX-1 was carried out using the
following primer 59-CATTTAACTGGGAAAACAGCCAAGA-
GAAGTGC-39. The mutation was confirmed by sequencing using
ABI PRISMH 3130 XL Genetic Analyzer (Applied Biosystems).
Antibodies and reagents
Mouse anti-myc IgG 9E10 (Invitrogen), mouse anti-V5 IgG
(Invitrogen), polyclonal rabbit anti-myc (Santa-Cruz), polyclonal
rabbit anti-ERK1/2 (Biosource, Invitrogen), mouse anti-phospho
ERK1/2 (Cell Signaling Technologies), mouse anti-b-actin IgG
(Affinity BioReagents) and rat anti-LOX-1 [18] were used as primary
antibodies. Goat anti-rat IgG horseradish peroxidase (HRP) was
purchased from Pierce, goat anti-mouse IgG HRP, donkey anti-
rabbit IgG HRP and Rhodamine Red TM-X-conjugated AffiniPure
donkey anti-mouse IgG from Jackson Immunoresearch. Peptide-N-
glycosidase F (PNGase-F) was purchased from New England Biolabs
(NEB), and proteases inhibitor cocktail set III from Calbiochem.
Cell cultures and transfection
COS cells were grown in DMEM medium (Euroclone)
supplemented with 10% foetal bovine serum (Gibco) and 100 U/
ml penicillin/streptomycin (Euroclone). Human monocytes were
isolated from peripheral blood mononuclear cells (PBMCs) from
buffy coats of volunteers and promoted their transition to
macrophages in vitro as described [26]. COS cells were transiently
transfected with Superfect (Qiagen) following the manufacturer’s
instructions, with a DNA/ transfectant reagent ratio (w/v) of 1:5.
Western blot and Immunoprecipitation
Transfected COS cells and human primary macrophages were
washed twice with ice-cold phosphate buffer saline, lysed for
20 minutes at 4uC in ice-cold extraction buffer (EB) containing
10 mM Tris/HCl pH 7.6, 100 mM NaCl, 10 mM EDTA, 0.5%
Nonidet P40, 0.5% sodium deoxycholate, proteases inhibitor
cocktail set III (0.1 mM AEBSF hydrochloride, 0.5 mM aprotinin,
5 mM Bestatin, 1.5 mM E-64, 10 mM Leupeptin, 1 mM Pepstatin
A and 1 mM phenylmethylsulfonyl fluoride) and centrifuged for
15 minutes at 4uC at 15,0006g. The supernatant fraction was
analysed by SDS-PAGE in 12% acrylamide gels and transferred to
polyvinylidene difluoride (PVDF) membranes (Amersham Bios-
cences) for 16 h at 30 V. Immunoreactive bands were visualized
by enhanced chemiluminescence (ECL, Sigma). For separation of
oligomeric forms, proteins were separated by NuPAGE 3–8%
Tris-Acetate Gels (Invitrogen) in non reducing conditions.
Immunoprecipitation with Mab anti-V5 and rabbit anti-myc
IgG was performed as previously described [18]. For removal of
N-linked glycans, clarified cellular lysates were MeOH-precipitat-
ed and digested with PNGase-F as previously described [18].
Immunofluorescence analysis and surface labelling
quantification
Cell membrane immunofluorescence was carried out as
described [25] using Mab anti-V5 as primary antibody and
Rhodamine RedTM-X-conjugated AffiniPure donkey anti-mouse
IgG as secondary antibody. Samples were examined with a
DMRA Leica fluorescence microscope, equipped with CCD
camera and with a confocal microscope (Nikon Instruments Spa,
C1 on Eclipse TE200; EZC1 software). CytoELISA assay for
quantification of membrane expressed proteins was performed as
previously described [18].
ERK 1/2 activation
COS cells were transiently transfected with K/K167, K/N167
and N/N167 LOX-1-V5 and LOXIN-V5 as described above. 48-
h after transfection, non-transfected and transfected COS cells
were incubated with different concentration (from 10 to 100 mg/
ml) of ox-LDL for 10 minutes at 37uC. After treatment, cells were
harvested, lysed and cell extracts were separated with SDS-PAGE
in 12% acrylamide gels and blotted. The levels of ERK1/2 were
detected by polyclonal antibodies directed against the C-terminal
region of the human protein and the activated kinase was detected
with mouse monoclonal antibodies directed against the phospho-
peptide corresponding to residues surrounding Thr202/Tyr204.
Immunoreactive bands were visualized by ECL. Densitometric
measurements were performed on a VersaDoc Imaging System
(BioRad).
Ox-LDL preparation, labelling and fluorometric assay
Human LDL was prepared from fresh healthy normolipidemic
plasma of volunteers by ultracentrifugation [27]. LDL was
oxidised and labelled with 1,19-dioctadecyl-3,3,39,39-tetramethyl-
lindocarbocyanine perchlorate (DiI) as previously described [18].
24 hours after transfection cells were incubated with (DiI)-labelled
ox-LDL in serum-free medium on ice for 1 hour in binding assay
and at 37uC for 4 h in uptake assay. DiI fluorescence was observed
with a DMRA Leica fluorescence microscope, equipped with
CCD camera. Quantitation of ox-LDL receptor activity in cells
was assayed by DiI extraction in isopropanol [28] and fluorescence
determined in a Perkin Elmer spectrofluorometer with excitation
and emission wavelengths set at 520 and 578 nm, respectively.
Molecular dynamics simulation
LOX-1 protein coordinates were obtained by X-ray [4,5] as
stored in the Protein Data Bank (PDB) (www.rcsb.org/pdb)
selecting the 1YPQ file, having the highest resolution (1.4 A ˚) [4].
In this structure, due to the absence of the LOX-1 neck domain,
the terminal ends of the CTLD domain are not uniformly
determined by X-ray diffraction. To avoid the presence of
asymmetric N and C termini the subunits sequences have been
made of the same length. Following the sequence numbering given
in the 1YPQ PDB file, 4 residues (from Arg136 to Asn139) have
been removed from the N-terminus of monomer B because they
are not present in the monomer A, and 3 residues (from Arg271 to
Gln273) in the conformation detected in the 1YPO LOX-1
structure [4], have been added to the C-terminus of both
monomers. The dioxane molecule, bound within the largest
tunnel chamber, has been removed from the structure whilst the
388 water molecules have been maintained and mixed with those
of the built simulation boxes. The modelling has been carried out
using the SYBYL 6.0 program (Tripos Inc. 1699, South Hanley
Road St. Louis, Missouri, 63144, USA).
The system topologies have been obtained with the AMBER
LeaP module [29], and modelled with the all-atoms AMBER95
force field [30,31]. The proteins have been immersed in
rectangular boxes filled with TIP3 water molecules [32] and the
three systems have been neutralized adding the necessary amount
of counterions in electrostatically preferred positions. The two
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using a cut-off radius of 9.0 A ˚ for the non-bonded interactions, and
updating the neighbour pair list every 10 steps. The electrostatic
interactions have been calculated with the Particle Mesh Ewald
method [33,34]. The SHAKE algorithm [35] has been used to
constrain all bond lengths involving hydrogen atoms. The systems
were simulated for a total of 15 ns at constant temperature of
300 K using Berendsen’s method [36] and at a constant pressure
of 1 bar with a 2.0 fs time step. Pressure and temperature coupling
constants were 0.4 ps. The atomic positions were saved every 250
steps (0.5 ps) and the last 10 ns has been used for the analysis. The
systems were simulated at CASPUR research center of Rome,
Italy (Inter Universities Consortium for Supercomputing Applica-
tions) on Power 4 IBM parallel computers by using an 8 CPU
cluster. The RMSF was calculated over the equilibrated MD
trajectories removing the global translations and rotations. The
time evolution of RMSD has been monitored using the
GROMACS MD package version 3.1.4 [37]. The salt bridges
have been calculated using the VMD program version 1.8.5 [38].
Electrostatic isopotential surfaces
The electrostatic isopotential surfaces of K/K167, N/N167 and
K/N167 LOX-1 receptors were calculated for selected frames of
the MD trajectories solving the Poisson-Boltzmann equation using
the DelPhi algorithm [39], as implemented in the GRASP
program version 1.2 [40]. The program numerically solves the
Poisson-Boltzmann equation by finite difference method (FDPB)
[41] and visualises the electrostatic isosurfaces on the rendered
molecular surface. Net charges were assigned to all ionizable
groups considered in their standard protonation state at pH 7
[42].
Statistical data analysis
Data are reported as means6S.E. Differences were tested for
significance using one-way ANOVA followed by Bonferoni’s test.
The significance level was chosen as p.0.05.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0004648.s001 (0.49 MB TIF)
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